Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

PURPOSE: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Disis, Mary L., Wallace, Danelle R., Gooley, Theodore A., Dang, Yushe, Slota, Meredith, Lu, Hailing, Coveler, Andrew L., Childs, Jennifer S., Higgins, Doreen M., Fintak, Patricia A., dela Rosa, Corazon, Tietje, Kathleen, Link, John, Waisman, James, Salazar, Lupe G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754913/
https://ncbi.nlm.nih.gov/pubmed/19720923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6789
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados